Interactions between the principal risk factors for reduction of the eGFR in unvaccinated COVID‑19 survivors: Normal pre-COVID‑19 eGFR, not having diabetes and being hospitalized

Guzman‑Esquivel,Jose; Diaz‑Martinez,Janet; Ortega‑Ortiz,Jose G.; Murillo‑Zamora,Efren; Melnikov,Valery; Tejeda‑Luna,Hector R.; Cosio‑Medina,Vanessa G.; Llerenas‑Aguirre,Karla I.; Guzman‑Solorzano,Jose A.; Hernandez‑Fuentes,Gustavo A.; Ochoa‑Castro,Maria R.; Cardenas‑Rojas,Martha I.; Rojas‑Larios,Fabian; Delgado‑Enciso,Ivan

doi:10.3892/etm.2023.12279

Interactions between the principal risk factors for reduction of the eGFR in unvaccinated COVID‑19 survivors: Normal pre-COVID‑19 eGFR, not having diabetes and being hospitalized

Authors:
- Jose Guzman‑Esquivel
- Janet Diaz‑Martinez
- Jose G. Ortega‑Ortiz
- Efren Murillo‑Zamora
- Valery Melnikov
- Hector R. Tejeda‑Luna
- Vanessa G. Cosio‑Medina
- Karla I. Llerenas‑Aguirre
- Jose A. Guzman‑Solorzano
- Gustavo A. Hernandez‑Fuentes
- Maria R. Ochoa‑Castro
- Martha I. Cardenas‑Rojas
- Fabian Rojas‑Larios
- Ivan Delgado‑Enciso
View Affiliations

Affiliations: Clinical Epidemiology Research Unit, Mexican Institute of Social Security, Villa de Alvarez, Colima 28984, Mexico, Research Center in Minority Institutions, Robert Stempel College of Public Health, Florida International University, Miami, FL 33199, USA, Nephrology Unit, Mexican Institute of Social Security, Colima 28000, Mexico, School of Medicine, University of Colima, Colima 28040, Mexico
Published online on: October 30, 2023 https://doi.org/10.3892/etm.2023.12279
Article Number: 580
Copyright: © Guzman‑Esquivel et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There are contradictory results regarding changes in estimated glomerular filtration rate (eGFR) in coronavirus disease 2019 (COVID‑19) survivors. An analysis of eGFR changes and clinical characteristics associated with those changes was conducted among COVID‑19 survivors. eGFR values were compared at different time points (before and 4‑, 8‑ and 12‑months after COVID‑19 infection). A multivariate generalized linear mixed model (GENLINMIXED procedure) with a binary logistic regression link was used to determine factors associated with eGFR reduction of ≥10 ml/min/1.73 m2. Being hospitalized (RR=2.90, 95% CI=1.10‑7.68, P=0.032), treated with Ivermectin (RR=14.02, 95% CI=4.11‑47.80, P<0.001) or anticoagulants (RR=6.51, 95% CI=2.69‑15.73, P<0.001) are risk factors for a reduced eGFR. Having a low eGFR (<90 ml/min/1.73 m2) before COVID‑19 infection, having B‑positive blood type, diabetes, taking vitamin C during the acute phase of COVID‑19 or suffering from chronic COVID‑19 symptoms, were identified as protective factors. Analysis involving a two‑way interaction (A x B, where A and B are factors) demonstrated that the combination of patients with a normal eGFR value before COVID‑19 infection without diabetes (RR=58.60, 95% CI=11.62‑295.38, P<0.001), or a normal eGFR value with being hospitalized for COVID‑19 (RR=38.07, 95% CI=8.68‑167.00, P<0.001), increased the probability of a reduced eGFR. The changes in eGFR in COVID‑19 survivors varied depending on patient characteristics. Furthermore, the principal risk factors for post‑COVID‑19 eGFR reduction were analyzed in separate models.

View Figures

View References

1	Guzman-Esquivel J, Mendoza-Hernandez MA, Guzman-Solorzano HP, Sarmiento-Hernandez KA, Rodriguez-Sanchez IP, Martinez-Fierro ML, Paz-Michel BA, Murillo-Zamora E, Rojas-Larios F, Lugo-Trampe A, et al: Clinical characteristics in the acute phase of COVID-19 that predict long COVID: Tachycardia, myalgias, severity, and use of antibiotics as main risk factors, while education and blood group B are protective. Healthcare (Basel). 11(197)2023.PubMed/NCBI View Article : Google Scholar
2	Delgado-Enciso I, Paz-Garcia J, Barajas-Saucedo CE, Mokay-Ramírez KA, Meza-Robles C, Lopez-Flores R, Delgado-Machuca M, Murillo-Zamora E, Toscano-Velazquez JA, Delgado-Enciso J, et al: Safety and efficacy of a COVID-19 treatment with nebulized and/or intravenous neutral electrolyzed saline combined with usual medical care vs usual medical care alone: A randomized, open-label, controlled trial. Exp Ther Med. 22(915)2021.PubMed/NCBI View Article : Google Scholar
3	Diao B, Wang C, Wang R, Feng Z, Zhang J, Yang H, Tan Y, Wang H, Wang C, Liu L, et al: Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Commun. 12(2506)2021.PubMed/NCBI View Article : Google Scholar
4	Yende S and Parikh CR: Long COVID and kidney disease. Nat Rev Nephrol. 17:792–793. 2021.PubMed/NCBI View Article : Google Scholar
5	Faour WH, Choaib A, Issa E, Choueiry FE, Shbaklo K, Alhajj M, Sawaya RT, Harhous Z, Alefishat E and Nader M: Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies. Inflamm Res. 71:39–56. 2022.PubMed/NCBI View Article : Google Scholar
6	Spruill WJ, Wade WE and Cobb HH III: Comparison of estimated glomerular filtration rate with estimated creatinine clearance in the dosing of drugs requiring adjustments in elderly patients with declining renal function. Am J Geriatr Pharmacother. 6:153–160. 2008.PubMed/NCBI View Article : Google Scholar
7	Tong M, Yan X, Jiang Y, Jin Z, Zhu S, Zou L, Liu Y, Zheng Q, Chen G, Gu R, et al: Endothelial biomarkers in patients recovered from COVID-19 one year after hospital discharge: A cross-sectional study. Mediterr J Hematol Infect Dis. 14(e2022033)2022.PubMed/NCBI View Article : Google Scholar
8	Nugent J, Aklilu A, Yamamoto Y, Simonov M, Li F, Biswas A, Ghazi L, Greenberg H, Mansour G, Moledina G and Wilson FP: Assessment of acute kidney injury and longitudinal kidney function after hospital discharge among patients with and without COVID-19. JAMA Netw Open. 4(e211095)2021.PubMed/NCBI View Article : Google Scholar
9	Zhou M, Tan X, Luo P, Xu J, Yin Z, Liao T, Wang S, Wang Z and Jin Y: Changes in glomerular filtration rate and metabolomic differences in severely ill coronavirus disease survivors 3 months after discharge. Biochim Biophys Acta Mol Basis Dis. 1868(166289)2022.PubMed/NCBI View Article : Google Scholar
10	Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N and Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 130:461–470. 1999.PubMed/NCBI View Article : Google Scholar
11	Ruggenenti P, Cortinovis M, Trillini M, Parvanova A, Abbate M, Satriano C, Salvetti F, Bossi AC, Trevisan R, Perna A, et al: Long-term kidney and systemic effects of calorie restriction in overweight or obese type 2 diabetic patients (C.Re.S.O. 2 randomized controlled trial). Diabetes Res Clin Pract. 185(109804)2022.PubMed/NCBI View Article : Google Scholar
12	McDonald JH: Biological statistics. 1st edition. California State, 2023.
13	Jaffa MA, Gebregziabher M, Luttrell DK, Luttrell LM and Jaffa AA: Multivariate generalized linear mixed models with random intercepts to analyze cardiovascular risk markers in type-1 diabetic patients. J Appl Stat. 43:1447–1464. 2016.PubMed/NCBI View Article : Google Scholar
14	Baum MK, Tamargo JA, Diaz-Martinez J, Delgado-Enciso I, Meade CS, Kirk GD, Mehta SH, Moore R, Kipke MD, Shoptaw SJ, et al: HIV, psychological resilience, and substance misuse during the COVID-19 pandemic: A multi-cohort study. Drug Alcohol Depend. 231(109230)2022.PubMed/NCBI View Article : Google Scholar
15	Rosner B: Fundamentals of biostatistics. 3rd edition. PWS-Kent Pub. Co, Boston, Mass, 1990.
16	Pewsner D, Battaglia M, Minder C, Marx A, Bucher HC and Egger M: Ruling a diagnosis in or out with ‘SpPIn’ and ‘SnNOut’: A note of caution. BMJ. 329:209–213. 2004.PubMed/NCBI View Article : Google Scholar
17	Hardenberg JHB and Luft FC: Covid-19, ACE2 and the kidney. Acta Physiol (Oxf). 230(e13539)2020.PubMed/NCBI View Article : Google Scholar
18	Rodrigues R and Costa De Oliveira S: The impact of angiotensin-converting enzyme 2 (ACE2) expression levels in patients with comorbidities on COVID-19 severity: A comprehensive review. Microorganisms. 9(1692)2021.PubMed/NCBI View Article : Google Scholar
19	Zavori L, Molnar T, Varnai R, Kanizsai A, Nagy L, Vadkerti B, Szirmay B, Schwarcz A and Csecsei P: Cystatin-c may indicate subclinical renal involvement, while orosomucoid is associated with fatigue in patients with long-COVID syndrome. J Pers Med. 13(371)2023.PubMed/NCBI View Article : Google Scholar
20	Torjesen I: Covid-19: Infection increases the risk of kidney disease even in mild cases, finds study. BMJ. 374(n2189)2021.PubMed/NCBI View Article : Google Scholar
21	Reis S, Popp M, Schießer S, Metzendorf MI, Kranke P, Meybohm P and Weibel S: Anticoagulation in COVID-19 patients-an updated systematic review and meta-analysis. Thromb Res. 219:40–48. 2022.PubMed/NCBI View Article : Google Scholar
22	Reis G, Silva EASM, Silva DCM, Thabane L, Milagres AC, Ferreira TS, Dos Santos CVQ, Campos VHS, Nogueira AMR, de Almeida APFG, et al: Effect of early treatment with Ivermectin among patients with COVID-19. N Engl J Med. 386:1721–1731. 2022.PubMed/NCBI View Article : Google Scholar
23	Furlan L: Ivermectin treatment for COVID-19. N Engl J Med. 387(e66)2022.PubMed/NCBI View Article : Google Scholar
24	Barus R, Gautier S and Wabont G: Ivermectin treatment for COVID-19. N Engl J Med. 387(e66)2022.
25	Arise RO and Malomo SO: Effects of ivermectin and albendazole on some liver and kidney function indices in rats. Afr J Biochem Res. 3:190–197. 2009.
26	Nunes LLA and Lima TDM: Use of medicines for COVID-19 treatment in patients with loss of kidney function: A narrative review. J Bras Nefrol. 43:254–262. 2021.PubMed/NCBI View Article : Google Scholar : (In English, Portuguese).
27	Tawfeek SE, Domouky AM and Abdel-Kareem RH: Protective effect of vitamin C against ivermectin induced nephrotoxicity in different age groups of male wistar rats: Bio-histopathological study. Anat Cell Biol. 54:501–517. 2021.PubMed/NCBI View Article : Google Scholar
28	Niki E: Action of ascorbic acid as a scavenger of active and stable oxygen radicals. Am J Clin Nutr. 54 (6 Suppl):1119S–1124S. 1991.PubMed/NCBI View Article : Google Scholar
29	GabAllh MS, El-mashad ABE, Amin AA and Darweish MM: Pathological studies on effects of ivermectin on male and female rabbits. Benha Vet Med J. 32:104–112. 2017.
30	Khawla B, Al-Deen A and Al-Masoudi EA, Majeed SK and Al-Masoudi EA: Histopathological and biochemical effects of ivermectin on kidney functions, lung, and the ameliorative effects of vitamin C in rabbits (lupus cuniculus). Basrah J Vet Res. 14:110–124. 2016.
31	Xu F, Wen Y, Hu X, Wang T and Chen G: The potential use of vitamin C to prevent kidney injury in patients with COVID-19. Diseases. 9(46)2021.PubMed/NCBI View Article : Google Scholar
32	Hazan S, Dave S, Gunaratne AW, Dolai S, Clancy RL, McCullough PA and Borody TJ: Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients. Future Microbiol. 17:339–350. 2022.PubMed/NCBI View Article : Google Scholar
33	May JM and Harrison FE: Role of vitamin C in the function of the vascular endothelium. Antioxid Redox Signal. 19:2068–2083. 2013.PubMed/NCBI View Article : Google Scholar
34	Rana R, Ranjan V and Kumar N: Association of ABO and Rh blood group in susceptibility, severity, and mortality of coronavirus disease 2019: A hospital-based study from Delhi, India. Front Cell Infect Microbiol. 11(767771)2021.PubMed/NCBI View Article : Google Scholar
35	Kim Y, Latz CA, DeCarlo CS, Lee S, Png CYM, Kibrik P, Sung E, Alabi O and Dua A: Relationship between blood type and outcomes following COVID-19 infection. Semin Vasc Surg. 34:125–131. 2021.PubMed/NCBI View Article : Google Scholar
36	Yang M, Xie J, Ouyang Y, Zhang X, Shi M, Li X, Wang Z, Shen P, Ren H, Zhang W, et al: ABO blood type is associated with renal outcomes in patients with IgA nephropathy. Oncotarget. 8:73603–73612. 2017.PubMed/NCBI View Article : Google Scholar